Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE (REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

Trial Profile

PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE (REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2019

At a glance

  • Drugs Palbociclib (Primary) ; Irinotecan; Temozolomide; Temozolomide
  • Indications CNS cancer; Ewing's sarcoma; Medulloblastoma; Neuroblastoma; Rhabdoid tumour; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Jan 2019 Planned End Date changed from 15 Nov 2023 to 18 Oct 2023.
    • 10 Jan 2019 Planned End Date changed from 13 Sep 2023 to 15 Nov 2023.
    • 10 Jan 2019 Planned primary completion date changed from 20 May 2020 to 23 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top